Adherium Reports Fourth Straight Quarter of Record RPM Revenue

Respiratory management specialist Adherium (ASX: ADR) has reported its fourth consecutive quarter of record remote patient monitoring (RPM) revenue with a total $479,000 achieved for the three months to end June.

The company continued to scale its RPM business during the period, driving further growth in recurring revenue and delivering quarter-on-quarter commercial momentum.

The growth has compounded into a proprietary, longitudinal dataset on real-world patient behaviour—an increasingly valuable strategic asset that differentiates Adherium in the respiratory market and underpins future clinical, commercial, and payer engagement.

Adherium’s 2026 target of 10,000 RPM device shipments provided a clear pathway to scaling its recurring revenue, with 3,831 activated patients at end June and 68,000 insurance-verified, device-compatible patients in the pipeline.

The RPM channel remains a key driver of near-term growth, providing Adherium with direct ownership of patient relationships, Hailie Smartinhaler data, and recurring revenue visibility while enabling to test, refine, and scale critical operational infrastructure across an expanding patient cohort.

Improving Patient Outcomes

Adherium’s Hailie Smartinhaler technology featured in data presented at a global conference of the American Thoracic Society.

Interim results from an independent Intermountain Health iCARE study showed how objective adherence data generated by Hailie devices — when combined with the CareCentra AI-driven remote monitoring platform — could support earlier intervention, improve patient outcomes, and reduce healthcare utilisation and total cost of care.

The study saw the supply of 4,000 Halie Smartinhalers, supporting up to 2,500 patients with asthma and chronic obstructive pulmonary disorder across five Intermountain Health facilities over two years.

It demonstrated strong persistence of the CareCentra platform, with more than 50% of active users staying engaged for over a year and the highest usage rates coming from elderly, high-risk patients, proving that technology-enabled support can make a lasting difference for those least likely to adopt or sustain digital health interventions.

Corporate and Capital News

Adherium appointed commercial healthcare executive John Perry to the role of chief commercial officer during the period, bringing with him more than 20 years of leadership in building and scaling value-based care businesses.

Mr Perry’s appointment marks the next phase of the company’s evolution, leveraging the proven Hailie Care clinical and data infrastructure to build a respiratory population health business that converts outcomes data into enterprise value-based revenue.

Non-executive director George Baran (who is also executive chair of majority shareholder Trudell Medical) has assumed the role of Adherium non-executive chair.

Adherium recorded a total of $408,000 in customer cash receipts for period, representing a 79% increase on $228,000 achieved in the March quarter.

At end June, the company had $1.38 million cash at hand compared to $2.95m in the March quarter.